Cargando…

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffin, David R., Richmond, Preston P., Olson, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://www.ncbi.nlm.nih.gov/pubmed/25505976
http://dx.doi.org/10.1155/2014/497178
_version_ 1782347872180633600
author Griffin, David R.
Richmond, Preston P.
Olson, John C.
author_facet Griffin, David R.
Richmond, Preston P.
Olson, John C.
author_sort Griffin, David R.
collection PubMed
description Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab. Snellen visual acuity and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final). Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses to aflibercept. Results. At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96). For whole group analysis, baseline and final central retinal thickness were 370.57 µm and 295.7 µm (P ≤ .001), respectively. Baseline and final retinal fluid volumes were 4.81 mm(3) and 4.37 mm(3) (P ≤ .001), respectively. Baseline and final logMAR were 0.56 and 0.53 (P = 0.301), respectively. Anatomic location of persistent exudate did not appreciably alter treatment outcome. Conclusion. Central retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients following three aflibercept injections. No appreciable change in visual acuity was noted.
format Online
Article
Text
id pubmed-4258314
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-42583142014-12-11 Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration Griffin, David R. Richmond, Preston P. Olson, John C. J Ophthalmol Clinical Study Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab. Snellen visual acuity and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final). Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses to aflibercept. Results. At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96). For whole group analysis, baseline and final central retinal thickness were 370.57 µm and 295.7 µm (P ≤ .001), respectively. Baseline and final retinal fluid volumes were 4.81 mm(3) and 4.37 mm(3) (P ≤ .001), respectively. Baseline and final logMAR were 0.56 and 0.53 (P = 0.301), respectively. Anatomic location of persistent exudate did not appreciably alter treatment outcome. Conclusion. Central retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients following three aflibercept injections. No appreciable change in visual acuity was noted. Hindawi Publishing Corporation 2014 2014-11-20 /pmc/articles/PMC4258314/ /pubmed/25505976 http://dx.doi.org/10.1155/2014/497178 Text en Copyright © 2014 David R. Griffin et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Griffin, David R.
Richmond, Preston P.
Olson, John C.
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title_full Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title_fullStr Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title_full_unstemmed Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title_short Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
title_sort intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and/or ranibizumab for neovascular age-related macular degeneration
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://www.ncbi.nlm.nih.gov/pubmed/25505976
http://dx.doi.org/10.1155/2014/497178
work_keys_str_mv AT griffindavidr intravitrealafliberceptoutcomesinpatientswithpersistentmacularexudatepreviouslytreatedwithbevacizumabandorranibizumabforneovascularagerelatedmaculardegeneration
AT richmondprestonp intravitrealafliberceptoutcomesinpatientswithpersistentmacularexudatepreviouslytreatedwithbevacizumabandorranibizumabforneovascularagerelatedmaculardegeneration
AT olsonjohnc intravitrealafliberceptoutcomesinpatientswithpersistentmacularexudatepreviouslytreatedwithbevacizumabandorranibizumabforneovascularagerelatedmaculardegeneration